Nimotuzumab Combined With Neoadjuvant Chemotherapy in the Treatment of Resectable LA HNSCC

NCT05351762 · clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
55
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Xijing Hospital